Figure 6: The levels of RANKL/OPG after treatment with 1,25(OH)2D3, MTX, and 1,25(OH)2D3 plus MTX in RA patients. The RA patients’ PBMCs are treated with either anti-CD3/CD28, or 1,25(OH)2D3 and MTX at various concentrations, or the combination of 1,25(OH)2D3 and MTX (D2M2 group). There was no difference in RANKL/OPG expression between the groups of 1,25(OH)2D3, MTX, and D2M2 and the group of vehicle ( ).